clopidogrel / acetylsalicylic acid

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for DuoPlavin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DuoPlavin.

This EPAR was last updated on 29/11/2019

Authorisation details

Product details
Agency product number
Active substance
  • clopidogrel
  • acetylsalicylic acid
International non-proprietary name (INN) or common name
clopidogrel / acetylsalicylic acid
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
sanofi-aventis groupe
Date of issue of marketing authorisation valid throughout the European Union
Contact address

54 rue La Boetie
75008 Paris

Product information

14/11/2019 DuoPlavin - EMEA/H/C/001143 - T/0054


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:

  • non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention;
  • ST-segment-elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.

Assessment history

How useful was this page?

Add your rating